European research and generic/biosimilar industry associations have called for an integrated life science strategy for Europe ahead of the adoption of the European Commission Work Program.
The European Federation of Pharmaceutical Industries and Associations (EFPIA), and the European Generic medicines Association (EGA) reiterated their joint Europe 2020 Strategy submission to welcome Commission President Juncker Commission’s work program for an industrial policy for the globalization era.
The joint submission asserts that the EU pharma sector can compete globally if the EU:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze